While subtype-based therapies, such as tarlatamab, which targets DLL3, a downstream target of ASCL1, are moving towards clinical application [42], the concurrent transcriptional activity of ASCL1 and NEUROD1 in SCLC-A/N, as demonstrated in our study, may complicate treatment strategies. Here, DLL3 is linked to small cell lung carcinoma.